Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2006

01.08.2006 | Original article

123/125I-labelled 2-iodo-L-phenylalanine and 2-iodo-D-phenylalanine: comparative uptake in various tumour types and biodistribution in mice

verfasst von: Veerle Kersemans, Bart Cornelissen, Ken Kersemans, Matthias Bauwens, Rudi A. Dierckx, Bart De Spiegeleer, John Mertens, Guido Slegers

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In vitro in the R1M cell model and in vivo in the R1M tumour-bearing athymic model, both [123I]-2-iodo-L-phenylalanine and [123I]-2-iodo-D-phenylalanine have shown promising results as tumour diagnostic agents for SPECT. In order to compare these two amino acid analogues and to examine whether the observed characteristics could be generalised, both isomers were evaluated in various tumour models.

Methods

Transport type characterisation in vitro in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M cells with [123I]-2-iodo-L-phenylalanine was performed using the method described by Shotwell et al. Subsequently, [123I]-2-iodo-L-phenylalanine and [123I]-2-iodo-D-phenylalanine tumour uptake and biodistribution were evaluated using dynamic planar imaging and/or dissection in A549, A2058, C6, C32, Capan2, EF43fgf4, HT29 and R1M inoculated athymic mice. Two-compartment blood modelling of the imaging results was performed.

Results

In vitro testing demonstrated that [123I]-2-iodo-L-phenylalanine was transported in all tumour cell lines by LAT1. In all tumour models, the two amino acid analogues showed the same general biodistribution characteristics: high and specific tumour uptake and renal tracer clearance. Two-compartment modelling revealed that the D-isomer showed a faster blood clearance together with a faster distribution to the peripheral compartment in comparison with [123I]-2-iodo-L-phenylalanine.

Conclusion

[123I]-2-iodo-L-phenylalanine and its D-isomer are promising tumour diagnostic agents for dynamic planar imaging. They showed a high and similar uptake in all tested tumours. [123I]-2-iodo-D-phenylalanine showed better tracer characteristics concerning radiation dose to other organs.
Literatur
1.
Hustinx R, Lemaire C, Jerusalem G, Moreau P, Cataldo D, Duysinx B, et al. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med 2003;44:533–539PubMed
2.
Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA, et al. Radiolabelled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–445PubMed
3.
Lahoutte T, Mertens J, Caveliers V, Franken PR, Everaert H, Bossuyt A, et al. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. J Nucl Med 2003;44:1489–1494PubMed
4.
Isselbacher KJ. Sugar and amino acid transport by cells in culture—differences between normal and malignant cells. Seminars in Medicine of the Beth Israel Hospital 1972;286:929–933
5.
Jager PL, De Vries EGE, Piers DA, Timmer-Bosscha H. Uptake mechanisms of L-3-[125I]-iodo-alpha-methyl-tyrosine in human small-cell lung cancer cell line: comparison with L-1-[14C]-tyrosine. Nucl Med Commun 2001;22:87–96CrossRefPubMed
6.
Tamemasa O, Goto R, Suzuki T. Preferential incorporation of some 11C-labeled D-amino acids into tumor bearing animals. Gann 1978;69:517–523PubMed
7.
Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transport system 1 (LAT1): characterisation of function and expression in tumour cell lines. Biochim Biophys Acta 2001;1514:291–302PubMedCrossRef
8.
Yang H, Zheng G, Peng X, Qiang B, Yuan J. D-Amino acids and D-Tyr-tRNATyr deacylase: stereospecificity of the translation machine revisited. FEBS Letters 2003;552:95–98CrossRefPubMed
9.
Kersemans B, Cornelissen K, et al. In Vivo Characterization of 123/1251-2-iodo-LPhenylalanine in an RIM Rhabdomyosarcoma Athymic Mouse Model as a Potential Tumor Tracer for SPECT. J Nucl Med 2005;46:532-539PubMed
10.
Kersemans V, Kersemans K, Cornelissen B, et al. In vivo evaluation of [I-123]-2-iodo-D-phenylalanine in tumour inoculated athymic mice by means of SPECT as a potential diagnostic and radionuclide therapy tool. Eur J Nucl Med 2004;31:S219 (meeting abstract)
11.
Shotwell MA, Jayme DW, Kilberg MS, Oxender DL. Neutral amino acid transport systems in Chinese hamster ovary cells. J Biol Chem 1981;256:5422–5427PubMed
12.
Mertens JJR, Kersemans V, Lahoutte T, Bauwens M, Joos C, Kersemans K, et al. Radioiodo-D-2-I-phenylalanine a new tumour specific tracer for diagnosis and systemic radionuclide therapy. Eur J Nucl Med Mol Imaging 2004;31:S220
13.
Waterton JC, Alott CP, Pickfort R, et al. Assessment of mouse tumour xenograft volumes in vivo by ultrasound imaging, MRI and calliper measurement. In: Faulkner K, Carey B, Crellin A, Harrison RM, editors. Proceedings of the 19th LH Gray Conference: Quantitative imaging in oncology. London; 1997 p. 146–149
14.
Cornelissen B, Kersemans V, Jans L, Staelens L, Oltenfreiter R, Thonissen T, et al. Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice. Br J Radiol 2005;78:338–342CrossRefPubMed
15.
Thie JA. Understanding the standardized uptake value, its methods and implications for usage. J Nucl Med 2004;45:1431–1434PubMed
16.
Langen KJ, Pauleit D, Coenen HH. 3-[123I]iodo-alpha-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2002;29:625–631CrossRefPubMed
17.
Vekeman M, Chavatte K, Lahoutte T, et al. L-[2-radioiodo] tyrosine, a new potential protein synthesis and tumour tracer for SPECT: radiosynthesis and biodistribution in rodent [abstract]. Eur J Nucl Med 1999;26:S43CrossRefPubMed
18.
Samnick S, Hellwig D, Bader JB, Romeike BF, Moringlane JR, Feiden W, et al. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumor imaging. Nucl Med Commun 2002;23:121–130CrossRefPubMed
19.
Samnick S, Richter S, Romeike BF, Heimann A, Feiden W, Kempski O, et al. Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats. Eur J Nucl Med 2000;27:1543–1551CrossRefPubMed
20.
Keyaerts M, Lahoutte T, Everaert H, et al. Initial clinical evaluation of 123-I-2-iodo-tyrosine in patients with brain tumours. (meeting abstract EANM 2005, Istanbul)
Metadaten
Titel
123/125I-labelled 2-iodo-L-phenylalanine and 2-iodo-D-phenylalanine: comparative uptake in various tumour types and biodistribution in mice
verfasst von
Veerle Kersemans
Bart Cornelissen
Ken Kersemans
Matthias Bauwens
Rudi A. Dierckx
Bart De Spiegeleer
John Mertens
Guido Slegers
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-0043-9

Weitere Artikel der Ausgabe 8/2006

European Journal of Nuclear Medicine and Molecular Imaging 8/2006 Zur Ausgabe

Original article

Disease activity and 18F-FDG uptake in organising pneumonia: semi-quantitative evaluation using computed tomography and positron emission tomography

Editorial

Putting ‘clear’ into nuclear medicine: a decade of PET/CT development

Focus on...

Time-of-flight PET and PET/MRI: recurrent dreams or actual realities?

Original article

Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy

Original article

Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept

Image of the month

Detection of widespread neurolymphomatosis with 18F-FDG PET